Abstract
Adenosine (ADO) is an endogenous inhibitory neuromodulator that increases nociceptive thresholds in response to tissue trauma and inflammation. Adenosine kinase (AK) is a key intracellular enzyme regulating intra- and extracellular concentrations of ADO. AK inhibition selectively amplifies extracellular ADO levels at cell and tissue sites where accelerated release of ADO occurs. AK inhibitors have been shown to provide effective antinociceptive, antiinflammatory and anticonvulsant activity in animal models, thus suggesting their potential therapeutic utility for pain, inflammation, epilepsy and possibly other central and peripheral nervous system diseases associated with cellular trauma and inflammation. This beneficial outcome may potentially lack nonspecific effects associated with the systemic administration of ADO receptor agonists. Until recently all of the reported AK inhibitors contained adenosine-like structural motif. The present review will discuss design, synthesis and analgesic and antiinflammatory properties of the novel nonnucleoside AK inhibitors that do not have close structural resemblance with the natural substrate ADO. Two classes of the nonnucleoside AK inhibitors are built on pyridopyrimidine and alkynylpyrimidine cores.
Keywords: adenosine kinase inhibitor, adenosine, pyridopyrimidines, alkynylpyrimidines, analgesia, Inflammation
Current Pharmaceutical Design
Title: Nonnucleoside Inhibitors of Adenosine Kinase
Volume: 10 Issue: 10
Author(s): Arthur Gomtsyan and Chih-Hung Lee
Affiliation:
Keywords: adenosine kinase inhibitor, adenosine, pyridopyrimidines, alkynylpyrimidines, analgesia, Inflammation
Abstract: Adenosine (ADO) is an endogenous inhibitory neuromodulator that increases nociceptive thresholds in response to tissue trauma and inflammation. Adenosine kinase (AK) is a key intracellular enzyme regulating intra- and extracellular concentrations of ADO. AK inhibition selectively amplifies extracellular ADO levels at cell and tissue sites where accelerated release of ADO occurs. AK inhibitors have been shown to provide effective antinociceptive, antiinflammatory and anticonvulsant activity in animal models, thus suggesting their potential therapeutic utility for pain, inflammation, epilepsy and possibly other central and peripheral nervous system diseases associated with cellular trauma and inflammation. This beneficial outcome may potentially lack nonspecific effects associated with the systemic administration of ADO receptor agonists. Until recently all of the reported AK inhibitors contained adenosine-like structural motif. The present review will discuss design, synthesis and analgesic and antiinflammatory properties of the novel nonnucleoside AK inhibitors that do not have close structural resemblance with the natural substrate ADO. Two classes of the nonnucleoside AK inhibitors are built on pyridopyrimidine and alkynylpyrimidine cores.
Export Options
About this article
Cite this article as:
Gomtsyan Arthur and Lee Chih-Hung, Nonnucleoside Inhibitors of Adenosine Kinase, Current Pharmaceutical Design 2004; 10 (10) . https://dx.doi.org/10.2174/1381612043452703
DOI https://dx.doi.org/10.2174/1381612043452703 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Neuroinflammation on ABC Transporters: Possible Contribution to Refractory Epilepsy
CNS & Neurological Disorders - Drug Targets Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Isoform Selective Voltage-Gated Sodium Channel Modulators and the Therapy of Pain
Current Medicinal Chemistry In Silico Validation and Structure Activity Relationship Study of a Series of Pyridine-3-carbohydrazide Derivatives as Potential Anticonvulsants in Generalized and Partial Seizures
Central Nervous System Agents in Medicinal Chemistry Parallel Computing for Brain Simulation
Current Topics in Medicinal Chemistry A Review of the Diagnostic Scope of Biomarker Techniques, Genetic Screening and Virtual Scanning
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy How to Find Candidate Drug-targets for Antiepileptogenic Therapy?
Current Neuropharmacology Subject Index to Volume 9
Current Pharmaceutical Design Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design The Ability of MEAs Containing Cultured Neuroglial Networks to Process Information
Current Bioinformatics The Management and Alternative Therapies for Comorbid Sleep Disorders in Epilepsy
Current Neuropharmacology Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Patent Selections:
Recent Patents and Topics on Imaging (Discontinued)